Paving the way for anti-Abeta active immunotherapy
European Pharmaceutical Review
SEPTEMBER 22, 2023
The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.
Let's personalize your content